Details : RTA 744 (berubicin hydrochloride) is an anthracycline, which is designed to utilize natural processes to induce deoxyribonucleic acid (DNA) damage in targeted cancer cells. It is being evaluated in phase 2 clinical trials for the treatment of glioblastom...
Brand Name : Berubicin
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 18, 2023
Details : Berubicin treatment of brain cancer patients appeared to demonstrate positive responses that include one durable complete response in a Phase 1 human clinical trial conducted by Reata Pharmaceuticals, Inc.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 29, 2021
CNS Pharmaceuticals Completes Drug Product Manufacturing Strategy for Berubicin
Details : The Company decided to implement a dual-track drug product manufacturing strategy in order to mitigate both COVID-19 related risks, as well as to diversify its supply chain and reduce the risk that inefficiencies could impact the Company's clinical timel...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 15, 2020
CNS Pharmaceuticals Engages Berry Consultants to Advise Phase 2 Trial Design
Details : CNS Pharmaceuticals has engaged Berry Consultants, a leading clinical statistical consulting group, to advise the Company ahead of its Phase 2 trial regarding its lead drug candidate Berubicin.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 30, 2020
CNS Announces the FDA has Granted Orphan Drug Designation for Brain Cancer Drug Berubicin
Details : In the Phase 1 trial of Berubicin to treat glioblastoma, under a prior developer, 44% of the patients demonstrated a significant improvement in progression free survival, and one patient experienced a complete response.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 11, 2020
CNS Pharmaceuticals Announces Filing of FDA Orphan Drug Designation for Brain Cancer Drug Berubicin
Details : Designation based on the results of prior Phase 1 trial of Berubicin in which 44% of the patients demonstrated a significant improvement in progression free survival.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 23, 2020
CNS Pharmaceuticals Announces Brain Cancer Patient from Berubicin Phase 1 Trial Remains Cancer Free
Details : In the Phase 1 trial, 44% of patients experienced a statistically significant improvement in progression-free survival.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 03, 2020
Lead Product(s) : Berubicin
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
WPD Pharma to Conduct Clinical Trials in Pediatric Brain Tumors
Details : The Company, in collaboration with CNS, is planning to conduct the upcoming Phase I clinical trial at Children's Memorial Health Institute
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 12, 2020
Lead Product(s) : Berubicin
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : For the large scale production of Berubicin, its lead drug candidate for the treatment of glioma brain tumors.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 14, 2020
LOOKING FOR A SUPPLIER?